Anti-proliferative compounds for the prevention of restenosis: Anti-restenotic mechanisms of paclitaxel action

Current Pharmaceutical Design

Volumn 16, Issue 36, 2010, Pages 3989-4001

  Lavigne, Mark C ^a   Eppihimer, Michael J ^a   Cheng, Ruth ^a   Barry, James J ^a  

^a BOSTON SCIENTIFIC CORPORATION   (United States)

Author keywords

Angioplasty; Balloon; Diabetes; Drug eluting stent; Endothelial; Paclitaxel; Proliferation; Restenosis; Vascular smooth muscle

Indexed keywords

ABCIXIMAB; BATIMASTAT; DACTINOMYCIN; DEXAMETHASONE; ESTRADIOL; EVEROLIMUS; PACLITAXEL; ZOTAROLIMUS;

ARTERY INTIMA PROLIFERATION; ATHEROSCLEROTIC PLAQUE; BARE METAL STENT; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; DIABETES MELLITUS; DRUG ACTIVITY; DRUG BINDING; DRUG CHOICE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG ELUTING STENT; HEART PERFUSION; HUMAN; IMPLANTATION; IN-STENT RESTENOSIS; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTENOSIS; REVASCULARIZATION; REVIEW; THROMBOSIS;

CELL PROLIFERATION; CONSTRICTION, PATHOLOGIC; CORONARY ARTERY DISEASE; HUMANS; PACLITAXEL; STENTS;

EID: 79952674030     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210794454888     Document Type: Review

References (153)

1. Ross R. Atherosclerosis - An inflammatory disease. N Engl J Med 1999; 340(2): 115-26.
2. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of vulnerable plaque. J Am Coll Cardiol 2006; 47(8): C13-8.
3. Gruentzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary- artery stenosis: percutaneous transluminal coronay angioplasty. N Engl J Med 1979; 301: 61-8.
4. Holmes Jr DR, Vlietstra RE, Smith HC, et al. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute. Am J Cardiol 1984; 53: 77C-81.
5. Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation 2005; 111: 2257-73.
6. Komatsu R, Ueda M, Naruko T, Kojima A, Becker AE. Neointimal tissue response at sites of coronary stenting in humans. Macroscopic, histological and immunohistochemical analysis. Circulation 1998; 98: 224-33.
7. Casscells W. Migration of smooth muscle and endothelial cells: critical events in restenosis. Circulation 1992; 86: 723-29.
8. Chung IM, Gold HK, Schwartz SM, Ikari Y, Reidy TN. Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment. J Am Coll Cardiol 2002; 40: 2072-81.
9. Farb A, Kolodgie FD, Hwang J-Y, et al. Extracellular matrix changes in stented human coronary arteries. Circulation 2004; 110: 940-47.
10. Mekhail TM, Markman M. Paclitaxel in cancer therapy. Expert Opin Pharmacother 2002; 3(6): 755-66.
11. Colombo A, Drzewiecki J, Banning, et al. Randomized study to assess the effectiveness of slow- and moderate release polymer-based Paclitaxel-eluting stents for coronary artery lesions. Circulation 2003; 108: 788-94.
12. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-31.
13. Chong PH, Cheng JWM. Early experiences and clinical implications of drug-eluting stents: Part 1. Ann Pharmacother 2004; 38: 661-69.
14. Kibos A, Campeanu A, Tintoiu I. Pathophysiology of coronary artery in-stent restenosis. Acute Cardiac Care 2007; 9: 111-19.
15. Scott NA. Restenosis following implantation of bare metal coronary stents: Pathophysiology and pathways involved in the vascular response to injury. Adv Drug Del Rev 2006; 58: 358-76.
16. Hughes AD, Clunn GF, Refson J, Dmoliou-Mason C. Platelet-derived growth factor (PDGF): actions and mechanism in vascular smooth muscle. Gen Pharmacol 1996; 27(7): 1079-89.
17. Sironi M, Breviario F, Proserpio P, et al. IL-1 stimulates IL-6 production in endothelial cells. J Immunol 1989; 142(2): 549-53.
18. Kaplanski G, Farnarier C, Kaplanski S, et al. Interleukin-1 induces interleukin-8 secretion from endothelial cells by a juxtacrine mechanism. Blood 1994; 84(12): 4242-48.
19. Murao K, Ohyama T, Imachi H, et al. TNF-alpha stimulation of MCP-1 expression is mediated by the Akt/PKB signal transduction pathway in vascular endothelial cells. Biochem Biophys Res Commun 2000; 276(2): 791-96.
20. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J 1995; 9(10): 899-909.
21. Horvath C, Welt FG, Nedelman M, Rao P, Rogers C. Targeting CCR2 or CD18 inhibits experimental in-stent restenosis in primates: inhibitory potential depends on type of injury and leukocytes targeted. Circ Res 2002; 90: 488-94.
22. Rogers C, Welt FG, Karnovsky MJ, Edelman ER. Monocyte recruitment and neointimal hyperplasia in rabbits. Coupled inhibitory effects of heparin. Arterioscler Thromb Vasc Biol 1996; 16: 1312-18.
23. Lavigne MC, Eppihimer MJ. Leukocyte-endothelial cell interactions: A therapeutic target to ameliorate inflammatory diseases. Curr Med Chem Anti-Inflamm Anti-Allergy Agents 2003; 2: 325-50.
24. Inoue T, Uchida T, Yaguchi I, Sakai Y, Takayanagi K, Morooka S. Stent-induced expression and activation of the leukocyte integrin Mac-1 is associated with neointimal thickening and restenosis. Circulation 2003; 107: 1757-63.
25. The ERASER Investigators. Acute platelet inhibition with abcixi-mab does not reduce in-stent restenosis (ERASER study). Circulation 1999; 100(8): 799-806.
26. Clowes AW, Clowes MM. Regulation of smooth muscle proliferation by heparin in vitro and in vivo. Int Angiol 1987; 6(1): 45-51.
27. Majack RA, Clowes AW. Inhibition of vascular smooth muscle cell migration by heparin-like glycosaminoglycans. J Cell Physiol 1984; 118(3): 253-56.
28. Moer R, Myreng Y, Molstad P, et al. Stenting in small coronary arteries (SISCA) trial. A randomized comparison between balloon angioplasty and the heparin-coated be Stent. J Am Coll Cardiol 2001; 38(6): 1598-603.
29. Geary RL, Koyama N, Wang TW, Vergel S, Clowes AW. Failure of heparin to inhibit intimal hyperplasia in injured baboon arteries. The role of heparin-sensitive and -insensitive pathways in the stimulation of smooth muscle cell migration and proliferation. Circulation 1995; 91(12): 2972-81.
30. Castellot JJJ, Addonizio ML, Rosenberg RD, Karnovsky MJ. Cultured endothelial cells produce a heparin-like inhibition of smooth muscle cell growth. J Cell Biol 1981; 90: 372-79.
31. Van Belle E, Bauters C, Asahara T, Isner JM. Endothelial regrowth after arterial injury: from vascular repair to therapeutics. Cardiovasc Res 1998; 38: 54-68.
32. Rogers C, Parikh S, Seifert P, Edelman ER. Endogenous cell seeding: remnant endothelium after stenting enhances vascular repair. Circulation 1996; 94: 2909-14.
33. Farhat MY, Lavigne MC, Ramwell PW. The vascular protective effects of estrogen. FASEB J 1996; 10(5): 615-24.
34. Brouchet L, Krust A, Dupont S, Chambon P, Bayard F, Arnal JF. Estradiol accelerates reendothelialization in mouse carotid artery through estrogen receptor-alpha but not estrogen receptor beta. Circulation 2001; 103: 423-28.
35. Dai-Do D, Espinosa E, Liu G, et al. 17-beta-estradiol inhibits proliferation and migration of human vascular smooth muscle cells: similar effects in cells from postmenopausal females and in males. Cardiovasc Res 1996; 32:980-5.
36. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801-11.
37. Lantin-Hermoso RL, Rosenfeld CR, Yuhanna IS, German Z, Chen, Shaul PW. Estrogen acutely stimulates nitric oxide synthase activity in fetal pulmonary artery endothelium. Am J Physiol 1997; 273: L119-26.
38. 2+ mobilization. Circ Res 1997; 81:885-92.
39. Geraldes P, Sirois MG, Bernatchez PN, Tanguay JF. Estrogen regulation of endothelial and smooth muscle cell migration and proliferation: role of p38 and p42/44 mitogen-activated protein kinase. Arterioscler Thromb Vasc Biol 2002; 22(10): 1585-90.
40. Lavigne MC, Ramwell PW, Clarke R. Inhibition of estrogen receptor function promotes porcine coronary artery smooth muscle cell proliferation. Steroids 1999; 64(7): 472-80.
41. Vargas R, Wroblewska B, Rego A, Hatch J, Ramwell PW. Oestra-diol inhibits smooth muscle cell proliferation of pig coronary artery. Br J Pharmacol 1993; 109(3): 612-17.
42. Abizaid A, Albertal M, Costa MA, et al. First human experience with the 17-beta-estradiol-eluting stent: the Estrogen And Stents To Eliminate Restenosis (EASTER) trial. J Am Coll Cardiol 2004; 43(6): 1118-21.
43. Abizaid A, Chaves AJ, Leon MB, et al. Randomized, double-blind, multicenter study of the polymer-based 17-beta estradiol-eluting stent for treatment of native coronary artery lesions: six-month results of the ETHOS I trail. Catheter Cardiovasc Interv 2007; 70(5): 654-60.
44. Airoldi F, Di Mario C, Ribichini F, et al. 17-beta-estradiol eluting stent versus phosphorylcholine-coated stent for the treatment of native coronary artery disease. Am J Cardiol 2005; 96(5): 664-67.
45. Fox RI, Tornwall J, Michelson P. Current issues in the diagnosis and treatment of Sjogren's syndrome. Curr Opin Rheumatol 1999; 11(5): 364-71.
46. Dragatakis LN, Klassen J, Huttner I, Fraser DG, Poirier NL, Klassen GA. Autoimmune myocarditis: a clinical entity. CMAJ 1979; 120: 317-21.
47. Redford TW, Small RE. Update on pharmacotherapy of systemic lupus erythematosus. Am J Health Syst Pharm 1995; 52(23): 2686-95.
48. Gronemeyer H. Control of transcription activation by steroid hormone receptors. FASEB J 1992; 6: 2524-29.
49. Adcock IM. Glucocorticoid-regulated transcription factors. Pulm Pharmacol Ther 2001; 14: 211-19.
50. Sen CK, Packer L. Antioxidant and redox regulation of gene transcription. FASEB J 1996; 10(7): 709-20.
51. Lavigne MC, Queen J, Kunkel E, et al. Biological profiling of drugs for treatment of in-stent restenosis. FASEB J 2008; 22: 1148.1
52. Han SH, Ahn TH, Kang WC, et al. The favorable clinical and angiographic outcomes of a high-dose dexamethasone-eluting stent: randomized controlled prospective study. Am Heart J 2006; 152(5): 887 e1-7.
53. Konig A, Leibig M, Rieber J, et al. Randomized comparison of dexamethasone-eluting stents with bare metal stent implantation in patients with acute coronary syndrome: serial angiographic and sonographic analysis. Am Heart J 2007; 153(6): 979.e1-8.
54. Ribichini F, Tomai F, Paloscia L, et al. Steroid-eluting stents in patients with acute coronary syndrome: the dexamethasone eluting stent Italian registry. Heart 2007; 93(5): 598-600.
55. Pesarini G, Ferrero V, Tomai F, et al. Steroid-eluting stents in patients with acute coronary syndromes. Angiographic results of DESIRE: Dexmethasone-Eluting Stent Italian Registry. J Invasive Cardiol 2009; 21(3): 86-91.
56. Hoffmann R, Radke PW, Ortlepp JR, et al. Intravascular ultrasonic comparative analysis of degree of intimal hyperplasia produced by four different stents in the coronary arteries. Am J Cardiol 2004; 94(12): 1548-50.
57. Nilsson J, Sjolund M, Palmberg L, Thyberg J, Heldin C-H. Arterial smooth muscle cells in primary culture produce a platelet-derived growth factor-like protein. Proc Natl Acad Sci USA 1985; 82: 4418-22.
58. Kamath KR, Barry JJ, Miller KM. The Taxus drug-eluting stent: A new paradigm in controlled drug delivery. Adv Drug Del Rev 2006; 58: 412-36.
59. Serruys PW, Ormiston JA, Sianos G, et al. Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial. J Am Coll Cardiol 2004; 44(7): 1363-67.
60. Biondi-Zoccai GG, Agostoni P, Abbate A, et al. Adjusted indirect comparison of intracoronary drug-eluting stents: evidence from a metaanalysis of randomized bare-metal-stent-controlled trials. Int J Cardiol 2005; 100(1): 119-23.
61. Strauss BH, Robinson R, Batchelor WB, et al. In vivo collagen turnover following experimental balloon angioplasty injury and the role of matrix metalloproteinases. Circ Res 1996; 79(3): 541-50.
62. de Smet BJGL, de Kleijn D, Hanemaaijer R, et al. Metalloprotein-ase inhibition reduces constrictive arterial remodeling after balloon angioplasty. A study in the atherosclerotic Yucatan micropig. Circulation 2000; 101: 2962-67.
63. Araujo CM, Rando GA, Mauro MF, et al. Batimastat-eluting stent implantation for the treatment of coronary artery disease: results of the Brazilian pilot study. Arq Bras Cardiol 2005; 84(3): 256-60.
64. Bennett MR. In-stent restenosis: pathology and implications for the development of drug-eluting stents. Heart 2003; 89: 218-24.
65. Wessely R, Blaich B, BelAiba RS, et al. Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Thromb Haemost 2007; 97: 1003-12.
66. Parry TJ, Brosius R, Thyagarajan R, et al. Drug-eluting stents: Sirolimus and paclitaxel differentially affect cultured cells and injured arteries. Euro J Pharmacol 2005; 524: 19-29.
67. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993; 90: 9552-56.
68. Long BH, Fairchild CR. PTX inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telophase. Cancer Res 1994; 54: 4355-61.
69. Bhalla KN. Microtubule-targeted anticancer agents and apoptosis. Oncogene 2003; 22: 9075-86.
70. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
71. Blagosklonny MV, Darzynkiewicz Z, Dorata HH, et al. Paclitaxel induces primary and postmitotic G1 arrest in human arterial smooth muscle cells. Cell Cycle 2004; 3(8): 1050-56.
72. Lee RM, Masaki T, Yang H-S, et al. Different signaling responses to anti-proliferative agents in human aortic and venous smooth muscle cells. J Cell Biochem 2006; 99: 835-44.
73. Blagosklonny MV, Demidenko ZN, Giovino M, et al. Cytostatic activity of paclitaxel in coronary artery smooth muscle cells is mediated through transient mitotic arrest followed by permanent post-mitotic arrest. Comparison with cancer cells. Cell Cycle 2006; 5(14): 1574-79.
74. Minamino T, Komuro I. Vascular cell senescence - Contribution to atherosclerosis. Circ Res 2007; 100: 15-26.
75. Wantanabe T, Noritake J, Kaibuchi K. Regulation of microtubules in cell migration. Trends Cell Biol 2005; 15(2): 76-83.
76. Axel DI, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997; 96: 636-45.
77. Loscalzo J, Welch G. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 1995; 38(2): 87-104.
78. Wilson GJ, Nakazawa G, Schwartz RS, et al. Comparison of inflammatory response after implantation of Sirolimus- and Paclitaxel-eluting stents in porcine coronary arteries. Circulation 2009; 120: 141-49.
79. Lim SY, Jeong MH, Hong SJ, et al. Inflammation and delayed endothelialization with overlapping drug-eluting stents in a porcine model of in-stent restenosis. Circ J 2008; 72: 463-68.
80. Pendyala LK, Li J, Shinke T, et al. Endothelium-dependent vaso-motor dysfunction in pig coronary arteries with paclitaxel-eluting stent is associated with inflammation and oxidative stress. JACC Cardiovasc Interv 2009; 2(3): 253-62.
81. Wilson GJ, Polovick JE, Huibregtse BA, Poff BC. Overlapping paclitaxel-eluting stents: Long-term effects in a porcine coronary artery model. Cardiovasc Res 2007; 76: 361-72.
82. Welt GP and Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 2002; 22: 1769-76.
83. Sardella G, Mariani P, D'Alessandro M, et al. Early elevation of interleuin-1beta and interleukin-6 levels after bare or drug-eluting stent implantation in patients with stable angina. Thromb Res 2006; 117(6): 659-64.
84. Klitkou J, Jensen LO, Hansen HS, Thayssen P. High sensitive C-reactive protein and interleukin 6 are not related to neointimal hyperplasia in Paclitaxel eluting stents or bare metal stents. An intravascular ultrasound study. Int J Cardiol 2007; 119(1): 114-6.
85. Li JJ, Yan HB, Xiang XP, Qin XW, Zhang CY. Comparison of changes in early inflammatory markers between sirolimus- and Pa-clitaxel-eluting stent implantation. Cardiovasc Drugs Ther 2009; 23(2): 137-43.
86. Kang WC, Ahn TH, Moon CI, et al. Comparison of inflammatory markers and angiographic outcomes after implantation of sirolimus and paclitaxel-eluting stents. Heart 2009; 95(12): 970-5.
87. Strickler F, Richard R, Mcfadden S, et al. In vivo in vitro characterization of poly(styrene-b-isobutylene-b-styrene) copolymer stent coatings for biostability, vascular compatibility and mechanical integrity. J Biomed Mater Res 2010; 92A: 773-82.
88. Ellis SG, Stone GW, Cox DA, et al. Long-term safety and efficacy with Paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of de novo coronary disease using a single Paclitaxel-eluting stent). JACC Cardiovasc In-terv 2009; 2(12): 1248-59.
89. Leask A, Abraham DJ. TGF-p signaling and the fibrotic response. FASEB J 2004; 18(7): 816-27.
90. Nguyen KT, Shikh N, Wawro D, et al. Molecular responses of vascular smooth muscle cells to Paclitaxel-eluting bioresorbable stent materials. J Biomed Mater Res 2004; 69a: 513-24.
91. Drachman DE, Edelman ER, Seifert P, et al. Neointimal thickening after stent delivery of paclitaxel: Change in composition and arrest of growth over six months. J Am Coll Cardiol 2000; 36(7): 2325-32.
92. Schachner T, Steger C, Heiss S, et al. Paclitaxel treatment reduces neointimal hyperplasia in cultured human saphenous veins. Eur J Cardiothorac Surg 2007; 32(6): 906-11.
93. Kamath KR, Barry JJ. Textbook of interventional cardiovascular pharmacology. In: Kennedy C, Ed. London: Informa Healthcare 2007; pp. 299-312.
94. Lincoff AM, Topol EJ, Ellis SG. Local drug delivery for the prevention of restenosis. Fact, fancy, and future. Circulation 1994; 90(4): 2070-84.
95. Grube E, Lansky A, Hauptmann KE, et al. High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE randomized trial. J Am Coll Cardiol 2004; 44(7):1368-72.
96. Lansky AJ, Costa RA, Mintz GS, et al. Non-polymer-based pacli-taxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation 2004; 109(16): 1948-54.
97. Silber S. Paclitaxel-eluting stents: are they all equal? An analysis of six randomized controlled trials in de novo lesions of 3,319 patients. J Interv Cardiol 2003; 16(6): 485-90.
98. Tanabe K, Serruys PW, Grube E, et al. TAXUS III trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003; 107(4): 559-64.
99. Lasala JM, Stone GW, Dawkins KD, et al. An overview of the TAXUS Express, paclitaxel-eluting stent clinical trial program. J Interv Cardiol 2006; 19(5): 422-31.
100. Morice MC, Serruys PW, Kappetein AP, et al. Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy between percutaneous coronary intervention with TAXUS and cardiac surgery (SYNTAX) trial. Circulation 2010; 121(24): 2645-53.
101. Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005; 294(10): 1215-23.
102. Lasala JM, Cox DA, Morris DL, et al. Two-year results of paclitaxel-eluting stents in patients with medically treated diabetes mel-litus from the TAXUS ARRIVE program. Am J Cardiol 2009; 103(12): 1663-71.
103. Ansel GM, Lumsden AB. Evolving modalities for femoropopliteal interventions. J Endovasc Ther 2009; (2 Suppl 2): 1182-97.
104. Duda SH, Bosiers M, Lammer J, et al. Drug-eluting and bare niti-nol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther 2006; 13(6): 701-10.
105. Krol KL, Saxon RR, Farhat N, et al. Clinical evaluation of the Zilver vascular stent for symptomatic iliac artery disease. J Vasc Interv Radiol 2008; 19(1): 15-22.
106. Bosiers M, Deloose K, Keirse K, Verbist J, Peeters P. Are drug-eluting stents the future of SFA treatment? J Cardiovasc Surg 2010; 51(1): 115-9.
107. Lau K-W, Sigwart U. Molecular Interventions and Local Drug Delivery. In: Edelman ER, Levy RJ, Eds. London: WB Saunders Co Ltd. 1995; pp. 1-28.
108. De Labriolle A, Pakala R, Bonello L, Lemesle G, Scheinowitz M, Waksman R. Paclitaxel-eluting balloon: from bench to bed. Catheter Cardiovasc Interv 2009; 73(5): 643-52.
109. Tesfamariam B. Drug release kinetics from stent device-based delivery systems. J Cardiovasc Pharmacol 2008; 51(2): 118-25.
110. Scheller B, Speck U, Schmitt A, Böhm M, Nickenig G. Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol 2003; 42(8): 1415-20.
111. Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 2006; 355(20): 2113-24.
112. Sharma S, Kukreja N, Christopoulos C, Gorog DA. Drug-eluting balloon: new tool in the box. Expert Rev Med Devices 2010; 7(3): 381-8.
113. Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 2009; 119(23): 2986-94.
114. Scheller B, Hehrlein C, Bocksch W, et al. Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol 2008; 97(10): 773-81.
115. Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 2008; 358(7): 689-99.
116. Krucoff MW, Kereiakes DJ, Petersen JL, et al. A novel bioresorb-able polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. J Am Coll Cardiol 2008; 51(16): 1543-52.
117. Buszman P, Trznadel S, Milewski K, et al. Novel paclitaxel-eluting, biodegradable polymer coated stent in the treatment of de novo coronary lesions: a prospective multicenter registry. Catheter Cardiovasc Interv 2008; 71(1): 51-7.
118. Kandarpa K, Becker GJ, Hunink MG, et al. Transcatheter interventions for the treatment of peripheral atherosclerotic lesions: part I. J Vasc Interv Radiol 2001; 12: 683-95.
119. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 2000; 31(1 Pt 2): S1-S296.
120. Ferreira M, Lanziotti L, Monteiro M, et al. Superficial femoral artery recanalization with self-expanding nitinol stents: long-term follow-up results. Eur J Vasc Endovasc Surg 2007; 34: 702-08.
121. Dube H, Clifford AG, Barry CM, et al. Comparison of the vascular responses to balloon expandable stenting in the coronary and peripheral circulations: long-term results in an animal model using the TriMaxx stent. J Vasc Surg 2007; 45: 821-7.
122. Shammas NW, Kapalis MJ, Dippel EJ, et al. Clinical and angi-ographic predictors of restenosis following renal artery stenting. J Invasive Cardiol 2004; 16: 10-3.
123. Lugmayr HF, Holzer H, Kastner M, et al. Treatment of complex arteriosclerotic lesions with nitinol stents in the superficial femoral and popliteal arteries: a midterm follow-up. Radiology 2002; 222: 37-43.
124. Henry M, Henry I, Klonaris C, et al. Clinical experience with the OptiMed sinus stent in the peripheral arteries. J Endovasc Ther 2003; 10: 772-9.
125. Pasterkamp G, Schoneveld AH, van Wolferen W, et al. The impact of atherosclerotic arterial remodeling on percentage of luminal stenosis varies widely within the arterial system. A postmortem study. Arterioscler Thromb Vasc Biol 1997; 17(11: 3057-63.
126. Dalager S, Paaske WP, Kristensen IB, Laurberg JM, Falk E. Artery-related differences in atherosclerosis expression: implications for atherogenesis and dynamics in intima-media thickness. Stroke 2007; 38(10): 2698-705.
127. Dalager S, Falk E, Kristensen IB, Paaske WP. Plaque in superficial femoral arteries indicates generalized atherosclerosis and vulnerability to coronary death: an autopsy study. J Vasc Surg 2008; 47(2): 296-302.
128. Falk E, Dalager D, William P, Kristensen IB, Laurberg JM. Atherogenesis and dynamics in intima-media thickness artery-related differences in atherosclerosis expression: Implications for atherogenesis and dynamics in intima-media thickness. Stroke 2007; 38; 2698-705.
129. Machan L. Drug eluting stents in the infrainguinal circulation. Tech Vasc Interv Radiol 2004; 7(1):28-32.
130. Shouse HB, Nikanorov A, LaFlash D. Biomechanical forces in the femoropopliteal arterial segment. Endovasc Today 2005; 4: 60-6.
131. Mewissen MW. Primary nitinol stenting for femoropopliteal disease. J Endovasc Ther 2009; 16(2 Suppl 2): II63-81.
132. Voudoukis T, Liatsikos EN, Kagadis GC, et al. Application of paclitaxel-eluting metal stents in renal artery of pig model. J En-dourol 2007; 21(12): 1571-6.
133. Misra S, Thatipelli MR, Howe PW, et al. Preliminary study of the use of drug-eluting stents in atherosclerotic renal artery stenoses 4 mm in diameter or smaller. J Vasc Interv Radiol 2008; 19(6): 833-9
134. SSYLVIA Study Investigators. Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or Intracranial Arteries (SSYLVIA): study results. Stroke 2004; 35(6): 1388-92.
135. Chastain HD 2nd, Campbell MS, Iyer S, et al. Extracranial vertebral artery stent placement: in-hospital and follow-up results. J Neurosurg 1999; 91(4): 547-52.
136. Albuquerque FC, Fiorella D, Han P, Spetzler RF, McDougall CG. A reappraisal of angioplasty and stenting for the treatment of vertebral origin stenosis. Neurosurgery 2003; 53(3): 607-14.
137. Gupta R, Al-Ali F, Thomas AJ, et al. Safety, feasibility, and short-term follow-up of drug-eluting stent placement in the intracranial and extracranial circulation. Stroke 2006; 37(10): 2562-6.
138. Siablis D, Karnabatidis D, Katsanos K, et al. Infrapopliteal application of paclitaxel-eluting stents for critical limb ischemia: midterm angiographic and clinical results. J Vasc Interv Radiol 2007; 18: 1351-61.
139. Bosiers M, Cagiannos C, Deloose K, et al. Drug eluting stents in the management of peripheral arterial disease. Vasc Health Risk Manag 2008; 4: 553-9.
140. Dake M. Interim report on the Zilver PTX clinical trial. In: International Symposium on Endovascular Therapy. Hollywood, FL 2007.
141. Dake M. The Zilver PTX global registry and RCT. Endovasc Today 2008; 63-4.
142. Brunk D. Drug-eluting stent proves durable at 6- and 12-month follow-up. Surgery News 2008; 4: 12.
143. Puybasset L, Béa ML, Ghaleh B, Giudicelli JF, Berdeaux A. Coronary and systemic hemodynamic effects of sustained inhibition of nitric oxide synthesis in conscious dogs. Evidence for cross talk between nitric oxide and cyclooxygenase in coronary vessels. Circ Res 1996; 79(2): 343-57.
144. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90(3): 251-62.
145. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006; 113: 1888-904.
146. Patterson C, Mapera S, Li HH, et al. Comparative effects of pacli-taxel and rapamycin on smooth muscle migration and survival: role of AKT-dependent signaling. Arterioscler Thromb Vasc Biol 2006; 26(7): 1473-80.
147. Finn AV, John M, Nakazawa G, et al. Differential healing after sirolimus, paclitaxel, and bare metal stent placement in combination with peroxisome proliferator-activator receptor gamma agonists: requirement for mTOR/Akt2 in PPARgamma activation. Circ Res 2009; 105(10): 1003-12.
148. Mayor M, Malik AZ, Minor RJ Jr, et al. One-year outcomes from the TAXUS express stent versus cypher stent. Am J Cardiol 2009; 103(7): 930-6.
149. Rosner D, McCarthy N, Bennett M. Rapamycin inhibits human in stent restenosis vascular smooth muscle cells independently of pRB phosphorylation and p53. Cardiovasc Res 2005; 66(3): 601-10.
150. Maeshima Y, Sudhakar A, Lively JC, et al. Tumstatin, an endothe-lial cell-specific inhibitor of protein synthesis. Science 2002; 295(5552): 140-3.
151. Martin KA, Rzucidlo EM, Merenick BL, Fingar DC, Brown DJ, Wagner RJ, Powell RJ. The mTOR/p70 S6K1 pathway regulates vascular smooth muscle cell differentiation. Am J Physiol Cell Physiol 2004; 286(3): C507-17.
152. Leon MB, Allocco DJ, Dawkins KD, Baim DS. Late clinical events after drug-eluting stents: the interplay between stent-related and natural history-driven events. JACC Cardiovasc Interv 2009; 2(6): 504-12.
153. Bhatt DL, Kapadia SR, Bajzer CT, et al. Dual antiplatelet therapy with clopidogrel and aspirin after carotid artery stenting. J Invasive Cardiol 2001; 13(12): 767-771.